EGFR and lung cancer: Although preclinical data across different tumor types (56, 57) and early phase lung cancer clinical trials (58, 59) pointed to the potential utility of dual inhibition of VEGF and EGFR, phase III data of the dual inhibitor vandetanib suggest that this is not a promising approach to overcome acquired resistance to EGFR-TKIs in advanced NSCLC (60).